NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on the commercialization and development of its non-antibiotic anti-infective products, announces that it has signed a nationwide distribution agreement with AmerisourceBergen, one of the largest global pharmaceutical sourcing and distribution services companies.
Under the agreement, AmerisourceBergen will carry and distribute NovaBay’s Avenova™, a prescription lid and lash hygiene product for the management of debilitating eye conditions such as blepharitis, Meibomian gland dysfunction and associated dry eye, to independent and retail chain pharmacies across the U.S.
Combined with NovaBay’s previous distribution agreements with McKesson Corporation (NYSE: MCK), Cardinal Health (NYSE: CAH) and Vision Source, the largest independent optometry network in the U.S. representing 2,800 independent optometrist offices, the new agreement means that Avenova now will be available to the majority of the nation’s 67,000 pharmacies and in thousands of ophthalmologist and optometrist offices across the country.
“Our agreement with AmerisourceBergen represents yet another major achievement in our commercial strategy,” said Dr. Ron Najafi, Chairman and CEO of NovaBay. “Patients who can benefit from Avenova are now assured that the product will be available through almost every pharmacy in America.”
“While it’s early in the commercial launch, we are encouraged by the market initial acceptance of Avenova,” said Glenn Moro, Vice President of Sales and Marketing. “We now have sales representatives in major markets across the country calling on top-prescribing optometrists and ophthalmologists. Our agreement with AmerisourceBergen will further increase the effectiveness of our sales team by making Avenova accessible to virtually every patient.”
NovaBay’s Avenova is the only eye care product to contain Neutrox™, NovaBay’s name for its proprietary pure hypochlorous acid (HOCl). HOCl is a naturally occurring substance released by white blood cells to fight microbial invaders. Lab studies show that Avenova has potent antimicrobial activity in solution, yet is non-toxic to mammalian cells. Those studies also show it also neutralizes bacterial toxins.
Those properties enable the cleansing properties of Avenova to treat chronic and often-painful eye conditions, blepharitis and Meibomian gland dysfunction, suffered by an estimated 30 million Americans. Patients who’ve had blepharitis for years—along with their doctors—report Avenova has finally brought relief. Many eye doctors are also now using Avenova routinely in preparation for cataract surgery and other types of surgery, and to alleviate the symptoms of dry eye syndrome. Because Neutrox is not an antibiotic or steroid, there are no risks of bacterial resistance or side effects.
About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®
NovaBay Pharmaceuticals is a biopharmaceutical company focusing commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: the NEUTROX™ Family of Products, including AVENOVA™ for the eye care market and NEUTROPHASE® for wound care, which was initially cleared by FDA, and CELLERX™ for the dermatology market; and its AGANOCIDE® compounds, led by AURICLOSENE™. NovaBay is partnered in the U.S. and around the globe with: PBE, Inc. (USA), IHT, Inc. (USA), Galderma (France), Virbac (France), China Pioneer Pharma (China and Southeast Asia), Shin Poong Pharmaceuticals (South Korea), Biopharm (North African and Middle East), Sarmedic Ltd (Israel) and Alpha Pharma LLC (Ukraine).
*Avenova Skin and Wound Cleanser is intended for use under the supervision of healthcare professionals for cleansing and removal of foreign material, including microorganisms and debris from wounds, and for moistening absorbent wound dressings and cleaning minor cuts, minor burns, superficial abrasions, and minor irritations of the skin. It is also intended for moistening and debriding acute and chronic dermal lesions, such as Stage I to IV pressure ulcers, stasis ulcers, leg ulcers, diabetic foot ulcers, post-surgical wounds, first and second degree burns, and grafted and donor sites.
This release contains forward-looking statements and opinions regarding the commercial potential of Avenova, which are based upon management’s current expectations, assumptions, estimates, projections and beliefs. The words “believe,” “will,” “estimated,” “potential,” and “expectation,” are intended to identify the forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to the actual effectiveness of NovaBay products and unexpected adverse side effects or inadequate therapeutic efficacy of Avenova, and the risk that potential customers will not perceive the benefits of Avenova to be the same as NovaBay believes. Other risks relating to NovaBay and its products, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay’s latest Form 10-K and Form 10-Q filings with the Securities and Exchange Commission, especially under the heading “Risk Factors.” The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.
Stay informed on NovaBay’s progress:
Download our Mobile InvestorApp from the Apple Store or Google Play
Like us on Facebook
Follow us on Twitter
Connect with NovaBay on LinkedIn
Join us on Google+
Visit NovaBay’s Website
For NovaBay Avenova purchasing information, please contact:
Toll Free: 1-800-890-0329
For investor information, please contact:
Thomas J. Paulson
Chief Financial Officer
Contact Thomas Paulson